Is There a Generic Version of Mounjaro Available?
No, no generic version of Mounjaro (tirzepatide) is available in the US or elsewhere as of now. Eli Lilly holds multiple patents protecting the drug until at least 2036, blocking FDA approval of generics.[1][2]
When Do Mounjaro Patents Expire?
Key US patents for tirzepatide cover the compound, formulation, and use in diabetes/weight loss, expiring between 2035 and 2036. A formulation patent lasts until May 2036, with pediatric exclusivity possibly extending it to November 2036. No generics can launch before then without a settlement or court challenge.[1][2]
What About Compounded Versions?
Pharmacies have offered compounded tirzepatide copies during shortages, but the FDA ended the national shortage declaration in late 2024. Compounding is now restricted for most patients, limited to specific cases with documentation. These are not FDA-approved generics and carry risks like inconsistent dosing or contamination.[3]
Are Biosimilars Coming Soon?
Mounjaro is a synthetic peptide, not a biologic, so generics (not biosimilars) apply under the standard ANDA pathway. No ANDA filings are public yet due to patent barriers. Eli Lilly is defending patents aggressively, with ongoing litigation against potential challengers.[1][2]
How Does This Compare to Other GLP-1 Drugs?
| Drug | Generic Available? | Earliest Generic Entry |
|------|---------------------|-----------------------|
| Ozempic (semaglutide) | No | 2031–2032[1] |
| Wegovy (semaglutide) | No | 2030–2033[1] |
| Trulicity (dulaglutide) | No | 2033[1] |
| Zepbound (tirzepatide) | No | Same as Mounjaro (2036)[2] |
Novo Nordisk faces similar patent walls, but some Paragraph IV challenges are in court.
Who Makes Mounjaro and What Are the Alternatives?
Eli Lilly manufactures Mounjaro for type 2 diabetes (also branded as Zepbound for weight loss). Cheaper options include older generics like metformin or GLP-1s like Rybelsus (oral semaglutide, no generic yet). Compounded semaglutide remains available in some states despite FDA warnings.[3]
Sources
[1]: DrugPatentWatch.com - Tirzepatide Patents
[2]: DrugPatentWatch.com - Zepbound Patents
[3]: FDA Tirzepatide Shortage Update